Why the study?
The study was conducted to assess secondary prevention strategies and the impact of European Stroke Organisation Guideline recommendations after ischaemic stroke or transient ischaemic attack.
Does implementing ESO guideline recommendations for secondary prevention reduce mortality and recurrent cardiovascular events in patients with non-cardioembolic ischaemic stroke or TIA?
Does implementing ESO guideline recommendations for secondary prevention reduce mortality and recurrent cardiovascular events in patients with non-cardioembolic ischaemic stroke or TIA?
Answers are grounded in this paper and cite their sources.
Implementing ESO guidelines for secondary prevention, including dual BP therapy, intensive LDL lowering, and pioglitazone, is estimated to significantly reduce mortality and recurrent cardiovascular events after ischaemic stroke or TIA.
OBJECTIVES: We aimed to assess secondary prevention strategies after ischaemic stroke or transient ischaemic attack (TIA). MATERIALS AND METHODS: We investigated the impact of European Stroke Organisation (ESO) Guideline recommendations for secondary prevention on recurrent events among people with non-cardioembolic ischaemic stroke or TIA. We assessed the following interventions by survival analysis or modelling impacts from clinical trial data: two blood pressure (BP) drugs compared to one drug; LDL-cholesterol target <1.8 mmol/L; and pioglitazone therapy. Outcomes were mortality, major adverse cardiovascular events (MACE) and recurrent stroke or myocardial infarction (MI). RESULTS: We included 4,037 people admitted between 01/12/2015 to 31/12/2018: mean (SD) age 68.6 (12.9) years; 1984 (49.1 %) female and median (IQR) follow-up 2.2 (1.5-3.1) years. Prescription of two BP drugs was associated with reduced mortality in our sample of 2238 people with hypertension (HR 0.64, 95 %CI 0.51-0.81; P<0.001). We estimate an LDL-cholesterol target <1.8 mmol/L could reduce MACE incidence from 128 to 114 events (95 %CI 103-127) in our sample of 1024 people with LDL-cholesterol 1.8 mmol/L who were not already prescribed intensive lipid-lowering therapy over median (IQR) 2.2 (1.5-2.9) years follow-up (ARR 1.38 %, NNT 73). We estimate pioglitazone therapy could reduce incidence of recurrent stroke or MI from 192 to 169 events (95 %CI 156-185) in our sample of 1587 people with diabetes or insulin resistance over median (IQR) 2.4 (1.7-3.2) years follow-up (ARR 1.45 %, NNT 69). CONCLUSIONS: We estimate that implementing ESO guidelines in a Scottish population after ischaemic stroke or TIA would reduce mortality and recurrent cardiovascular events.
No takes yet. Share an insight, caveat, or question.
Smith et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: